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CHARACTERISTICS OF CHILDREN STARTING ART
A literature review of 30 paediatric studies or treatment 
programmes found that children receiving ART ranged 
from infants aged 2 months to adolescents aged 15 
years.5 Of 26 studies that reported age at ART initiation, 
19 (73%) showed a mean or median age at start of 
treatment of >5 years. Only two studies reported a 
median age at start of treatment of <2 years.
The majority of children assessed in this review had 
severe immunosuppression at initiation of ART. The 
proportion of children with a CD4 percentage <15% 
ranged from 56% to 96%.
Overall mortality during follow-up was mostly low, with 
a probability of survival at 1 year after initiation of ART 
of 84 - 97%. A study from Cote D’Ivoire reported over 
3 years of follow-up, with 92 - 93% survival 6 months 
after initiation of ART, 91% at 12 months, 88% at 18 - 
36 months and 86% at 42 months.
The majority of deaths occurred within 6 months of 
starting ART. The most commonly reported risk factor 
for death was low CD4 percentage at initiation of 
treatment. Age >12 - 18 months was among the other 
risk factors reported.
Data from the KIDS-ART-LINC Cohort Collaboration (an 
international epidemiological network in sub-Saharan 
Africa) concur with the above findings.6 They report 
children starting ART at an average of 4.9 years, with 
only 12% starting at <12 months. Seventy per cent of 
children starting ART had severe immunodeficiency. The 
2-year risk of death on ART was 6.9% (95% confidence 
interval (CI) 5.9 - 8.1%), and this was independently 
associated with immunodeficiency, adjusted hazard ratio 
(AHR) 2.95 (95% CI 1.49 - 5.83) and advanced clinical 
disease AHR 3.65 (95% CI 1.95 - 6.83). 
KIDS-ART-LINC shows an increase in mortality risk in 
children starting ART when severely immunodeficient 
compared with children who were not immunodeficient, 
with the probability of death at 6 months rising from 
1.8% to 7.8%.9 Twelve months after starting ART the 
probabilities of death are 2.2% and 8.2% respectively.
Of note, where the entry point is reported, the majority 
of children are identified and enrolled into ART 
programmes through health facilities when they are 
treated when clinically indicated rather than as infants 
through PMTCT programmes.   
Only two studies assessed in the literature review 
report how children were referred for ART.5 In a Kenyan 
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The most effective way to combat paediatric HIV infection is through good management of maternal health and 
prevention of mother-to-child transmission (PMTCT). However, by the end of 2007, of an estimated 33.2 million 
people living with HIV, 2.1 million were children. Of these 90% lived in sub-Saharan Africa and 420 000 were 
newly infected in that year.1 
Although in recent years the number of children treated with antiretroviral therapy (ART) has increased from 
about 75 000 in 2005 to almost 200 000 in 2007, many children living with HIV are not receiving treatment. 
Without it approximately 35% will die before their first birthday and 53% by the time they reach the age of 2 
years.2 By age 5 years it is estimated that 62 - 89% of children will have died.3,4
Emerging data from sub-Saharan Africa show that most children starting ART are doing so at older ages, usu-
ally 5 years or more, that most start at a late stage of the disease, and that mortality in the first few months of 
treatment remains high.5,6 
A recent study shows that starting treatment in early infancy can be lifesaving, and this has informed revisions in 
World Health Organization (WHO) guidelines7,8 (see WHO ‘Dear Health Care Provider’ letter, Fig. 1). At present the 
majority of children who could benefit from these recommendations are not being diagnosed or treated.
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programme 69% of children were referred following 
admission to hospital and the remaining children were 
from other outpatient clinics. In Cote D’Ivoire, the 
paediatric department or other health care settings 
referred 64% of children, 24% were referred through the 
people living with HIV/AIDS network and 12% through 
PMTCT programmes.
Programme data from Malawi show that only 1% of 
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PMTCT follow-up, with the vast majority (80%) enrolled 
for ART through hospital wards.10 
The WHO reports that only 8% of infants born to 
pregnant women with HIV in 2007 were tested for HIV 
before they were 2 months old.1 
EVIDENCE FOR EARLY TREATMENT FROM THE 
CHER STUDY
The Children with HIV Early Antiretroviral Therapy (CHER) 
study, conducted in South Africa, is looking at whether 
early limited ART until a child’s first or second birthday 
would have long-term benefit by delaying disease 
progression and/or delaying the time when long-term 
continuous ART needs to be initiated.7 In this study 377 
young infants aged 6 - 12 weeks with a CD4 percentage 
>25% were randomised to three arms: 
n  Arm 1: Deferred treatment – ART when the CD4 
percentage declined to <20% (25% if <1 year; based 
on WHO guidelines).
n  Arm 2: Short course (to first birthday) – ART with 
planned interruption at 1 year.
n  Arm 3: Long course (to second birthday) – ART with 
planned interruption at 2 years. 
ART was started or restarted in all arms when the CD4 
percentage fell to <20% (25% in infants from August 
2006) or the CD4 count fell to <1 000 cells/µl if age <12 
months, or if indicated by a clinical event.
All infants were drug-naïve except for PMTCT prophylaxis 
(either nevirapine (NVP) single dose to mother and baby 
- 68% arm 1; 64.3% arms 2/3, or NVP plus short-course 
zidovudine (AZT) - 21% arm 1; 20.2% arms 2/3). The 
infants’ ART regimen was AZT + lamivudine (3TC) + 
lopinavir/ritonavir (LPV/r).
Following a data safety monitoring board (DSMB) review 
on 20 June 2007, after the trial was fully recruited and 
at a median follow-up of 32 (range 20 - 48) weeks, the 
DSMB recommended modification to the study and the 
release of the results of arm 1 vs. arms 2/3 combined. 
They recommended that infants in arm 1 should be 
recalled urgently and assessed for ART initiation and 
that the trial follow-up should continue.
At the time of the review, 10 (4%) infants in arms 2/3 
and 4 (3.2%) in arm 1 were lost to follow-up. By the end 
of April 2007, 61 (59%) infants had initiated ART in arm 
1. A total of 30 infants had died: 10 (4%) in arms 2/3 and 
20 (16%) in arm 1 (hazard ratio (HR) 0.24 (95% CI 0.11 
– 0.52); p=0.0002).
Of the infants who died, 12 died at home from unknown 
causes. Causes of death in the 18 infants who died in 
hospital were gastroenteritis (4, arm 1; 4 arms 2/3), 
sepsis/pneumonia (5 arm 1; 0 arms 2/3), Pneumocystis 
jiroveci pneumonia/cytomegalovirus infection (3  arm 1; 
0 arms 2/3), sudden infant death syndrome (0 arm 1; 1 
arms 2/3), liver failure (0 arm 1,1 arms 2/3).
The investigators noted that the deaths in this study 
were not always from AIDS-defining causes and were 
often sudden.
The CHER study found that starting ART before 12 weeks 
of age reduced early mortality by a highly significant 
75% compared with starting at CD4 percentages <25% 
or guided by clinical symptoms. 
NEW WHO RECOMMENDATIONS
On 13 June 2008, following a technical review of these 
data and another small study conducted in South Africa 
that supports the CHER findings, the WHO revised their 
guidelines to recommend universal treatment of all 
HIV-infected infants <12 months of age.7,8,11 The WHO 
strongly recommends that ’All infants under 12 months 
of age with confirmed HIV infection should be started on 
ART, irrespective of clinical or immunological stage.’
In order to benefit from early treatment and to reduce 
their risk of disease and death, infants will need to be 
tested at the earliest opportunity. 
For diagnosing infants the WHO strongly recommends 
that:
n  Infants known to be HIV exposed, i.e. born to mothers 
in PMTCT programmes, have a virological test (HIV 
nucleic acid test) at 4 - 6 weeks of age.
n  Any infant presenting at a health facility with signs 
or symptoms that may be an indication for HIV, 
should initially be tested using an HIV antibody test 
with a positive test confirmed by virological testing 
if possible.
n  All infants should have their HIV status established at 
their first contact with the health system, preferably 
before 6 weeks of age (in most cases this will be 
established by asking the mother and checking her 
history of HIV testing).
n  They also conditionally recommend that infants 
<6 weeks of age in settings of high antenatal HIV 
prevalence (i.e. >1%) should be offered maternal or 
infant HIV antibody testing. 
The WHO recommends that infants are diagnosed using 
virological tests (HIV DNA polymerase chain reaction 
(PCR), HIV RNA PCR or bDNa or NASBA, or ultrasensitive 
p24 antigen). The HIV DNA PCR is the only test that can 
be performed using dried blood spot samples and is the 
most useful for early diagnosis in PMTCT follow-up. 
They also recommend that testing is performed around 
4 - 6 weeks for PMTCT follow-up, and whenever an infant 
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is sick or HIV is suspected in those known to be exposed. 
Testing at 4 weeks instead of at 6 weeks provides an 
additional 2 weeks to start treatment at a time when the 
infant is very vulnerable.
If virological testing is not available, the WHO 
recommends presumptive diagnosis in accordance with 
nationally defined algorithms. Based on data from the 
CHER study, they are refining an algorithm based on 
symptoms and signs of HIV at 6 weeks of age.12 Although 
lacking sensitivity, suggestive signs include oral thrush, 
hepatomegaly, splenomegaly, lymphadenopathy, diaper 
dermatitis, and clinical gastro-oesophageal disease 
(cough and/or vomiting during feeds).
STARTING TREATMENT
The guidelines recommend ART regimens as follows:
n  No maternal or infant antiretroviral exposure; exposure 
to antiretrovirals other than non-nucleoside reverse 
inhibitors; unknown exposure – NVP-containing triple 
ART.   
n  Maternal or infant single-dose NVP or maternal 
NNRTI-containing ART – PI-containing triple ART 
(usually LPV/r).
Paediatric formulations for children too young to 
swallow tablets have traditionally been liquids or syrups. 
These formulations are expensive and not easy to store or 
transport. Cost and logistical issues have prohibited their 
widespread use. This example illustrates the challenge 
faced by the caregiver: ’A 10 kg child being treated with 
standard doses of stavudine, lamivudine, and nevirapine, 
for whom a 3-month supply of drugs is dispensed at a 
clinic visit, would require 18 bottles of liquid weighing 
almost half as much as the child (4.3 kg). For a rural 
family who may have walked a long distance to reach 
the clinical centre, this is a significant issue.’13
More recently manufacturers have developed more 
convenient crushable mini-pills or dispersable 
formulations and fixed-dose combinations, which can be 
used by very young children.14-16 Many programmes are 
now using these formulations and the WHO recommends 
dosing according to its simplified weight band tables 
(see Fig. 2).
The WHO have also identified data and formulations that 
need to be provided as a matter of urgency in order to 
support the revised recommendations: 
n Additional data on dosing of efavirenz (EFV) for young 
children and infants
n  Dosing for LPV/r for the group under 6 months and 5 
kg based on a target dose of 300 mg/m2
n LPV/r sprinkles (50/12.5 mg)
n Atazanavir/ritonavir (ATV/r) (heat stable)
n Ritonavir (RTV) (solid, heat-stable forms).
COMMENT
These recommendations from the WHO are welcome, 
and having a single ’one size fits all‘ policy that can be 
implemented without waiting for CD4 results will make 
Number of tablets or ml by weight band (twice daily) 
Children 6 weeks of age and above 








Strength of tab 











































AZT 60 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300 1 1 
AZT (new annex 
E) 
300; 10 mg/ml 6 ml 6 ml 6 ml 9 ml 9 ml 9 ml 9 ml 12 ml 12 ml 12 ml 0.5 0.5 0.75 300 1 1 
AZT/3TC 60/30 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300/150 1 1 
AZT/3TC/NVP 60/30/50 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300/150/200 1 1 
ABC 60 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300 1 1 
ABC (new annex 
E) 
300; 20 mg/ml 3 ml 3 ml 3 ml 4 ml 4 ml 4 ml 4 ml 6 ml 6 ml 6 ml 0.5 0.5 0.75 300 1 1 
ABC/3TC 60/30 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300/150 1 1 
ABC/3TC/NVP 60/30/50 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300/150/200 1 1 
ABC/AZT/3TC 60/60/30 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 300/300/150 1 1 
3TC 30 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 150 1 1 
3TC (new annex 
E) 
150; 10 mg/ml 3 ml 3 ml 3 ml 4 ml 4 ml 4 ml 4 ml 6 ml 6 ml 6 ml 0.5 0.5 0.75 150 1 1 
d4T 6 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 30 1 1 
d4T (new annex 
E) 













30 1 1 
d4T/3TC 6/30 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 30/150 1 1 
d4T/3TC/NVP 6/30/50 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 30/150/200 1 1 
NVP 50 1 1 1 1.5 1.5 1.5 1.5 2 2 2 2.5 2.5 3 200 1 1 
NVP (new annex 
E) 
200; 10 mg/ml 5 ml 5 ml 5 ml 8 ml 8 ml 8 ml 8 ml 10 ml 10ml 10 ml 0.75 0.75 0.75 200 1 1 























* 3 tablets BD of 100/25 may be substituted with 2 tablets am and 1 tablet pm of 200/50 
Note: higher doses of Lop/rit may be required when co-administered with enzyme-inducing drugs such as NVP, EFV; fosamprenavir, 
rifampicin.  
          
Fig. 2. Summary of simplified dosage of antiretrovirals for infants and children.
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starting paediatric ART more feasible. Nevertheless, 
implementing universal treatment for HIV-positive 
infants will be no small matter. Data show that currently 
only a few young infants are being identified and enrolled 
in treatment programmes in sub-Saharan Africa. The 
majority of children who receive ART are being diagnosed 
and start at about 5 years old, by which time many who 
needed it will have died.   
The CHER investigators wrote that their results ’… support 
the need for enhanced PMTCT programmes, early infant 
diagnosis and effective transition to care’. 
Firstly, then, the focus on PMTCT deserves emphasis. 
Identifying and treating an HIV-positive pregnant woman 
who meets the eligibility criteria for ART or ensuring that 
a healthier HIV-positive woman receives an effective 
prophylaxis regimen (some would say ART for all) – and 
in turn avoiding the majority of paediatric infections 
– surely must be a massive priority. Taking appropriate 
care of an easier-to-manage adult patient can avoid an 
additional, more complicated paediatric case, and where 
this has not been possible, the goal of universal ART for 
HIV-positive infants will be far easier to achieve with 
lower mother-to-child transmission rates. 
Secondly, running DNA PCR tests in order to 
diagnose infants early enough to benefit from these 
recommendations is not going to be feasible in many 
places. Low-cost, simple diagnostic assays are urgently 
needed.  In the meantime improved clinical and laboratory-
based algorithms are expected to refine the specificity 
of presumptive diagnosis. Clear recommendations are 
needed for repeat testing in breastfeeding populations.   
Thirdly, better links between PMTCT and treatment 
programmes for those children who are infected are 
important and will reduce delays in starting infants on 
ART.
Finally, we need good data to give guidance as to whether, 
once started, ART can be safely stopped in children after 
early initiation, and if it can, when the best time will be 
to resume therapy. 
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